Unapproved marketed drug 4 - Avadel Pharmaceuticals
Alternative Names: UMD 4 - Avadel Pharmaceuticals; UMD#4 - Avadel Pharmaceuticals; Unapproved marketed drug#4 - Avadel Pharmaceuticals; Undisclosed drug#4 - Avadel PharmaceuticalsLatest Information Update: 17 Feb 2026
At a glance
- Originator Eclat Pharmaceuticals
- Developer Avadel Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 12 Feb 2026 Avadel Pharmaceuticals has been acquired by Alkermes plc
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Undefined in USA
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals